Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

J. Thomas, Stephen; D. Moreira, Edson; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; L. Perez, John; Pérez Marc, Gonzalo; P. Polack, Fernando; Zerbini, Cristiano; Bailey, Ruth; A. Swanson, Kena; Xu, Xia; Roychoudhury, Satrajit; Koury, Kenneth; Bouguermouh, Salim; V. Kalina, Warren; Cooper, David; W. Frenck, Robert; L. Hammitt, Laura; Türeci, Özlem; Nell, Haylene; Schaefer, Axel; Ünal, Serhat; Yang, Qi; Liberator, Paul; B. Tresnan, Dina; Mather, Susan; R. Dormitzer, Philip; Şahin, Uğur; C. Gruber, William; U. Jansen, Kathrin

doi:10.1056/nejmoa2110345

Public

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Published in New England Journal of Medicine • Sep 15, 2021

Authors:

Stephen J. Thomas

Edson D. Moreira

Nicholas Kitchin

Abstract

BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-1...

Subject

Medicine

Messenger RNA

MEDLINE

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!